No relationship between 18F-fluorodeoxyglucose positron emission tomography and expression of Glut-1 and -3 and hexokinase I and II in high-grade glioma

Oncology Reports

Volumn 20, Issue 3, 2008, Pages 537-542

  Charnley, Natalie ^a   Airley, R ^b   Du Plessis, D ^c   West, C ^a   Brock, C ^d   Barnett, C ^e   Matthews, J ^a   Symonds, K ^b   Bottomly, M ^a   Swindell, R ^a   Price, P ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c HOPE HOSPITAL   (United Kingdom)

^d CHARING CROSS HOSPITAL   (United Kingdom)

^e SIEMENS AG   (Germany)

Author keywords

18F fluorodeoxyglucose; Glucose transporter; Hexokinase; High grade glioma; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; HEXOKINASE; HEXOKINASE 2; HEXOKINASE ISOENZYME; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; GLUCOSE; HK1 PROTEIN, HUMAN; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; GLIOBLASTOMA; GLIOMA; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METABOLIC RATE; OPTIMAL DRUG DOSE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR BIOPSY; TUMOR NECROSIS; TUMOR RECURRENCE; ASTROCYTOMA; BRAIN TUMOR; ENZYME IMMUNOASSAY; METABOLISM; METHODOLOGY; PATHOLOGY; PROGNOSIS; SCINTISCANNING;

ASTROCYTOMA; BRAIN NEOPLASMS; FLUORODEOXYGLUCOSE F18; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 3; HEXOKINASE; HUMANS; IMMUNOENZYME TECHNIQUES; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 54549127102     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000039     Document Type: Article

References (21)

1. Michiels C, Minet E, Michel G, Mottet D, Piret JP and Raes M: HIF-1 and AP-1 cooperate to increase gene expression in hypoxia: role of MAP kinases. IUBMB Life 52: 49-53, 2001.
2. Merrall NW, Plevin R and Gould GW: Growth factors, mitogens, oncogenes and the regulation of glucose transport. Cell Signal 5: 667-675, 1993.
3. Airley R, Loncaster J, Davidson S, et al: Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 7: 928-934, 2001.
4. Shepherd PR, Gould GW, Colville CA, McCoid SC, Gibbs EM and Kahn BB: Distribution of GLUT3 glucose transporter protein in human tissues. Biochem Biophys Res Commun 188: 149-154, 1992.
5. Schwab DA and Wilson JE: Complete amino acid sequence of rat brain hexokinase, deduced from the cloned cDNA, and proposed structure of a mammalian hexokinase. Proc Natl Acad Sci USA 86: 2563-2567, 1989.
6. Bennett MJ, Timperley WR, Taylor CB and Hill AS: Isoenzymes of hexokinase in the developing, normal and neoplastic human brain. Eur J Cancer 14: 189-193, 1978.
7. Weber G: Enzymology of cancer cells (second of two parts). N Engl J Med 296: 541-551, 1977.
8. Yen TC, See LC, Lai CH, et al: 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med 45: 22-29, 2004.
9. Kato H, Takita J, Miyazaki T, et al: Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma. Anticancer Res 23: 3263-3272, 2003.
10. Kurokawa T, Yoshida Y, Kawahara K, et al: Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 109: 926-932, 2004.
11. Chung JK, Lee YJ, Kim SK, Jeong JM, Lee DS and Lee MC: Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun 25: 11-17, 2004.
12. Brock CS, Young H, O'Reilly SM, et al: Early evaluation of tumour metabolic response using [18F]fluorodeoxy-glucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer 82: 608-615, 2000.
13. Brown RS, Goodman TM, Zasadny KR, Greenson JK and Wahl RL: Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol 29: 443-453, 2002.
14. Higashi T, Saga T, Nakamoto Y, et al: Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 43: 173-180, 2002.
15. Zhao S, Kuge Y, Mochizuki T, et al: Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med 46: 675-682, 2005.
16. Oliver RJ, Woodwards RT, Sloan P, Thakker NS, Stratford IJ and Airley RE: Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC Translational Research Fund studies. Eur J Cancer 40: 503-507, 2004.
17. Francavilla TL, Miletich RS, Di Chiro G, Patronas NJ, Rizzoli HV and Wright DC: Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. Neurosurgery 24: 1-5, 1989.
18. Herholz K, Wienhard K and Heiss WD: Validity of PET studies in brain tumors. Cerebrovasc Brain Metab Rev 2: 240-265, 1990.
19. Herholz K, Ziffling P, Staffen W, Pawlik G, Wagner R, Wienhard K and Heiss WD: Uncoupling of hexose transport and phosphorylation in human gliomas demonstrated by PET. Eur J Cancer Clin Oncol 24: 1139-1150, 1988.
20. Langdown ML and Sugden MC: Enhanced placental GLUT1 and GLUT3 expression in dexamethasone-induced fetal growth retardation. Mol Cell Endocrinol 185: 109-117, 2001.
21. Duelli R and Kuschinsky W: Brain glucose transporters: relationship to local energy demand. News Physiol Sci 16: 71-76, 2001.